Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
06/21/18Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 21, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5th annual series of “RNAi Roundtable” webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company’s late-stage pipeline... 
Printer Friendly Version
06/20/18Alnylam Expands Senior Leadership Team with Two Key Appointments
− Company Appoints Senior Vice President, Head of Asia and Senior Vice President, Head of Medical Affairs – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L. Marantz, M.D., Ph.D., as Senior Vice President, Head of Medica... 
Printer Friendly Version
06/15/18Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at the 4th Congress of the European Academy of Neurology (EAN), being held June 16-19, 2018 in Lisbon, Portugal. ... 
Printer Friendly Version
06/12/18Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day
– Alnylam Supports 23 Local Organizations in the Greater Boston Area and Western Europe – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide “Helping Hands” Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area and seven organizations in Western Europe. ... 
Printer Friendly Version
06/08/18Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
− Patients Receiving Investigational Lumasiran Experienced Substantial and Sustained Reductions in Urinary Oxalate, Confirming Potential for RNAi-Mediated Inhibition of Glycolate Oxidase as a Robust Therapeutic Approach for PH1 – − Lumasiran Generally Well Tolerated with no Treatment-Related Serious Adverse Events or Study Discontinuations – − Company Remains on Track to Initiate Lumasiran Phase 3 Study in Mid-2018 – CAM... 
Printer Friendly Version
06/04/18Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. ALN-TTRsc02 has the potential to be a once-quarterly, low volume, subcutaneously administered RNA... 
Printer Friendly Version
05/29/18Alnylam to Webcast Presentations at Upcoming June Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand Hyatt in New York City Jefferies 2018 Global Healthcare Conference on Wednesday, ... 
Printer Friendly Version
05/15/18Alnylam Appoints Colleen Reitan to the Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylam’s Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of Health Care Service Corporation (HCSC), the largest customer-owned health insurer in the United States and an independent ... 
Printer Friendly Version
05/08/18Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
− Novel siRNA Conjugates Achieve Robust, Durable, and Broadly Distributed Silencing of CNS Gene Transcripts Following a Single Intrathecal Injection – − Company Expects First CNS-Targeted Development Candidate in 2018, First IND in Late 2019/Early 2020, and Capacity for Sustained Pipeline of One or More CNS INDs per Year Thereafter − CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), t... 
Printer Friendly Version
05/03/18Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
− FDA Endorses Primary Endpoint of Reduction of Urinary Oxalate at Six Months for Pivotal Study Design − − Company Intends to Initiate Lumasiran Phase 3 Study in Mid-2018, with Topline Results Expected in 2019 and, if Positive, an NDA Submission Anticipated in Early 2020 − CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the... 
Printer Friendly Version
05/03/18Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
– Presented Positive New Clinical Results from APOLLO Phase 3 Study of Patisiran, and Phase 1 and Phase 1/2 Open-Label Extension (OLE) Studies of Givosiran – – Advanced Two Additional RNAi Therapeutics in Phase 3 Development: Inclisiran in ORION-9, -10, and -11 Studies, and Fitusiran in the ATLAS Program – – Company Provides Positive New Development Updates on Phase 3 Programs for Givosiran and Lumasiran – – Maintain... 
Printer Friendly Version
05/01/18Alnylam to Webcast Presentations at Upcoming May Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Deutsche Bank 43rd Annual Healthcare Conference on Tuesday, May 8, 2018 at 8:00 am ET at the InterContinental Hotel in Boston Bank of America Merrill Lynch 2018 Healthcare Conference on ... 
Printer Friendly Version
04/26/18Alnylam to Webcast Conference Call Discussing First Quarter 2018 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2018 on Thursday, May 3, 2018, after the U.S. financial markets close. Management will provide an update on the Company and discuss first quarter 2018 results as well as expectations for the future via confe... 
Printer Friendly Version
04/24/18Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting
− In New Post-Hoc Analysis, Patisiran Reduced the Composite Rate of All-Cause Hospitalization and Mortality by Approximately 50 Percent, Relative to Placebo − − In Addition, Patisiran Demonstrated Improvement in Multiple Quality of Life Measures, Compared to Placebo − − Analysis of Alnylam Act™ Genetic Testing Program Shows Identification of Pathogenic Transthyretin (TTR) Mutations in Approximately 7.5 Percent of Samples – ... 
Printer Friendly Version
04/23/18Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 23, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic, for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-me... 
Printer Friendly Version
04/20/18Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 20, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has entered into a settlement agreement with Dicerna Pharmaceuticals resolving trade secret misappropriation claims against Dicerna, and counterclaims asserted by Dicerna, in pending litigation in the Superior Court of Middlesex County, Massachusetts. The settlement also resolves claims ass... 
Printer Friendly Version
04/14/18Alnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
− In Randomized, Double-Blind, Placebo-Controlled Phase 1 Study, Monthly Givosiran Demonstrated an Over 80 Percent Lowering of Urinary Aminolevulinic Acid (ALA), a Disease Biomarker, and an Over 75 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Placebo − − Evidence of Enhanced Clinical Activity with Long-Term Treatment of up to 22 Months in Ongoing Phase 1/2 Open-Label Extension (OLE) Study, with an Over 90 Percent Decreas... 
Printer Friendly Version
03/28/18Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
− Patisiran Demonstrated Improvement of Cardiomyopathy in Prospectively Defined Subgroup of Patients with Cardiac Amyloid Involvement, Relative to Placebo − − Long-term Treatment with Patisiran in Global Open-Label Extension (OLE) Study Demonstrates Maintenance of Efficacy and Consistent Safety − − Degree of Patisiran-Mediated TTR Knockdown Found to Correlate with Neurologic Improvement – − New Phase 1 Data on ALN-TTRsc02, ... 
Printer Friendly Version
03/28/18Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)
− Updated Results to be Presented from Clinical Studies of Givosiran, an Investigational RNAi Therapeutic for the Treatment of AHPs − − In Addition, Data to be Presented from EXPLORE Natural History Study Characterizing the Burden of Disease in AHPs − CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and... 
Printer Friendly Version
03/26/18Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
− Company Intends to Advance Lumasiran to a Phase 3 Study in Late 2018 − CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 26, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for lumasiran (ALN-GO1), an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Prim... 
Printer Friendly Version
03/21/18Alnylam to Webcast Presentation at 17th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 21, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018 at 10:00 am ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the ... 
Printer Friendly Version
03/21/18Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)
Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases TARRYTOWN, N.Y. and CAMBRIDGE, Mass., March 21, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced a collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and potentially other related diseases.... 
Printer Friendly Version
03/14/18Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 14, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at the 16th International Symposium on Amyloidosis (ISA), being held March 26-29, 2018 in Kumamoto, Japan. In addition, new d... 
Printer Friendly Version
03/13/18Alnylam Unveils Resources to ‘Bridge the Gap’ in Knowledge of Hereditary ATTR (hATTR) Amyloidosis Among Families at Risk
— hATTRBridge.com features “Living a Rare Life” — one family’s story of living with this rare, genetic condition and the power of discussing family health history — CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2018-- For many people living with a rare disease, such as hereditary ATTR (hATTR) amyloidosis, it can take years to be accurately diagnosed. Moreover, many may not realize that the symptoms they are experiencing can be tied to their fami... 
Printer Friendly Version
03/12/18Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
− Company Plans to Accelerate Development with Phase 3 Start in Late 2018 − − Lumasiran Granted Breakthrough Therapy Designation by the United States Food and Drug Administration − CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 12, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Sanofi Genzyme has declined its opt-in for the development and commercialization of lumasiran ... 
Printer Friendly Version
03/06/18Alnylam to Webcast Presentations at Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen and Company 38th Annual Healthcare Conference on Tuesday, March 13, 2018 at 12:00 pm ET at the Boston Marriott Copley Place in Boston Barclays Global Healthcare Conferenc... 
Printer Friendly Version
02/08/18Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
– Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively – – Advanced Three Additional RNAi Therapeutics in Phase 3 Development, Including Givosiran in ENVISION, Inclisiran in ORION-9, -10, and -11, and Restart of Fitusiran in ATLAS – – S... 
Printer Friendly Version
02/05/18Alnylam to Webcast Presentations at Upcoming February Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 20th Annual BIO CEO & Investor Conference on Monday, February 12, 2018 at 10:45 am ET at the Marriott Marquis in New York City Leerink Partners 7th Annual Global Healthcare... 
Printer Friendly Version
02/01/18Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2017 results as well as expectations ... 
Printer Friendly Version
02/01/18Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
– PDUFA date set for August 11, 2018 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis. The FD... 
Printer Friendly Version
01/25/18Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
– EMA Will Evaluate MAA Under Accelerated Assessment – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 25, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated its review for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary AT... 
Printer Friendly Version
01/07/18Alnylam Announces 2018 Corporate Goals
Patisiran Expected to be First Commercially Available RNAi Therapeutic in Mid-2018 Restructured Sanofi Alliance Provides Alnylam with Global Commercial Footprint for ATTR Amyloidosis Givosiran Interim Phase 3 Data Expected in Mid-2018 and U.S. New Drug Application Filing Anticipated in Late 2018 Company Plans to Advance Three Additional Phase 3 Programs: Fitusiran, Inclisiran, and ALN-TTRsc02 Company Updates ... 
Printer Friendly Version
01/07/18Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
– Restructuring Enables Streamlined Development and Optimization of Commercial Opportunities for ATTR Amyloidosis and Hemophilia Programs – – Alnylam Obtains Global Rights for Investigational ATTR Amyloidosis Programs: Patisiran and ALN-TTRsc02 – – Sanofi Obtains Global Rights for Investigational Therapeutic Fitusiran in Hemophilia and Other Rare Bleeding Disorders – – Alnylam to Host Conference Call Today, Sunday, January 7 at 4:... 
Printer Friendly Version
01/04/18Alnylam Expands Alnylam Act™ Program to Include No-Charge Third-Party Genetic Testing and Counseling for People at Risk for Acute Hepatic Porphyrias
– Individuals with Acute Hepatic Porphyrias (AHPs), a Family of Ultra-Rare Genetic Diseases, are Often Misdiagnosed and May Experience an Average Delay in Diagnosis of 15 Years – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has expanded the Alnylam Act™ program to include no-charge, third-party genetic testing and counseling for... 
Printer Friendly Version
01/02/18Alnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 8:00 am PT (11:00 am ET) at The Westin St. Francis in San Francisco. In addition, the company will webcast the Q&A breakout session immediately following its present... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.